60,925 Qiagen N.V. $QGEN Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC trimmed its holdings in Qiagen N.V. (NYSE:QGEN – Free Report) by 47.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,402 shares of the company’s stock after selling 60,925 shares during the period. Intech Investment Management LLC’s holdings in Qiagen were worth $3,003,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of QGEN. Amundi lifted its position in shares of Qiagen by 12.4% during the first quarter. Amundi now owns 4,757,681 shares of the company’s stock worth $190,498,000 after acquiring an additional 524,959 shares in the last quarter. State Street Corp grew its position in shares of Qiagen by 4.5% in the second quarter. State Street Corp now owns 2,183,206 shares of the company’s stock valued at $85,363,000 after purchasing an additional 93,575 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Qiagen by 20.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company’s stock valued at $66,649,000 after purchasing an additional 286,665 shares in the last quarter. Swiss National Bank raised its stake in shares of Qiagen by 21.1% during the 1st quarter. Swiss National Bank now owns 716,059 shares of the company’s stock valued at $28,686,000 after purchasing an additional 124,920 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in shares of Qiagen by 10.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 381,762 shares of the company’s stock valued at $16,706,000 after purchasing an additional 37,355 shares during the period. Institutional investors own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on QGEN shares. Citigroup reissued a “neutral” rating and set a $52.00 price objective (up from $45.00) on shares of Qiagen in a report on Monday, October 26th. JPMorgan Chase & Co. cut Qiagen from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $55.00 to $52.00 in a research report on Thursday, October 22nd. DZ Bank downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 22nd. Robert W. Baird raised their price objective on shares of Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price objective on shares of Qiagen in a research note on Thursday, August 6th. Four equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $46.34.

Check Out Our Latest Research Report on Qiagen

Qiagen Price Performance

Qiagen stock opened at $49.30 on Friday. The stock has a market cap of $10.16 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 3.99 and a beta of 0.56. The company has a quick ratio of 2.14, a current ratio of 2.63 and a debt-to-equity ratio of 0.43. The business has a 50-day simple moving average of $47.21 and a 200 day simple moving average of $42.57. Qiagen N.V. has a 52 week low of $32.53 and a 52 week high of $57.81.

Qiagen (NYSE:QGEN – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. The firm had revenue of $547.87 million during the quarter, compared to the consensus estimate of $538.61 million. Qiagen had a return on equity of 14.70% and a net margin of 18.19%. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter last year, the company posted $0.61 EPS. On average, research analysts forecast that Qiagen N.V. will post 2.44 earnings per share for the current fiscal year.

Qiagen Profile

(Free Report)

QIAGEN is a life sciences company that develops technologies used to prepare and analyze biological samples. Its products help researchers and clinicians extract and process DNA, RNA and proteins from samples such as blood, tissue and other biological materials. The company offers laboratory consumables, instruments and software for molecular diagnostics and life sciences research, as well as applications in pharmaceutical research and applied testing. Its portfolio includes sample-preparation kits, molecular testing assays and platforms for PCR, digital PCR and next-generation sequencing.

Featured Articles

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN – Free Report).

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.